[1]
|
Mashima, R., Yamanashi, Y., Hishida, Y. and Tezuka, T. (2009) The Roles of Dok Family Adapters in Immunoreceptor Signaling. Immunological Reviews, 232, 273-285. https://doi.org/10.1111/j.1600-065X.2009.00844.x
|
[2]
|
Grimm, J., Sachs, M., Britsch, S., et al. (2001) Novel p62dok Family Members, dok-4 and dok-5, Are Substrates of the c-Ret Receptor Tyrosine Kinase and Mediate Neuronal Differentiation. Journal of Cell Biology, 154, 345-354.
https://doi.org/10.1083/jcb.200102032
|
[3]
|
Okada, K., Inoue, A., Okada, M., et al. (2006) The Muscle Protein Dok-7 Is Essential for Neuromuscular Synaptogenesis. Science, 312, 1802-1805. https://doi.org/10.1126/science.1127142
|
[4]
|
Di Cristofano, A., Carpino, N., Dunant, N., et al. (1998) Molecular Cloning and Characterization of p56dok-2 Defines a New Family of RasGAP-Binding Proteins. Journal of Biological Chemistry, 273, 4827-4830.
https://doi.org/10.1074/jbc.273.9.4827
|
[5]
|
Lemay, S., Davidson, D., Latour, S., et al. (2000) Dok-3, a Novel Adapter Molecule Involved in the Negative Regulation of Immunoreceptor Signaling. Molecular and Cellular Biology, 20, 2743-2754.
https://doi.org/10.1128/MCB.20.8.2743-2754.2000
|
[6]
|
He, P.F., Xu, Z.J., Zhou, J.D., et al. (2018) Methyla-tion-Associated DOK1 and DOK2 Down-Regulation: Potential Biomarkers for Predicting Adverse Prognosis in Acute Myeloid Leukemia. Journal of Cellular Physiology, 233, 6604-6614. https://doi.org/10.1002/jcp.26271
|
[7]
|
Zhang, L., Li, R., Hu, K., et al. (2019) Prognostic Role of DOK Family Adapters in Acute Myeloid Leukemia. Cancer Gene Therapy, 26, 305-312. https://doi.org/10.1038/s41417-018-0052-z
|
[8]
|
Yasuda, T., Bundo, K., Hino, A., et al. (2007) Dok-1 and Dok-2 Are Negative Regulators of T Cell Receptor Signaling. International Immunology, 19, 487-495. https://doi.org/10.1093/intimm/dxm015
|
[9]
|
Celis-Gutierrez, J., Boyron, M., Walzer, T., et al. (2014) Dok1 and Dok2 Proteins Regulate Natural Killer Cell Development and Function. EMBO Journal, 33, 1928-1940. https://doi.org/10.15252/embj.201387404
|
[10]
|
Laroche-Lefebvre, C., Yousefi, M., Daudelin, J.F., et al. (2016) Dok-1 and Dok-2 Regulate the Formation of Memory CD8+ T Cells. The Journal of Immunology, 197, 3618-3627. https://doi.org/10.4049/jimmunol.1600385
|
[11]
|
周瑜, 丁佑铭, 周文波. 酪氨酸激酶下游蛋白基因与肿瘤关系的研究进展[J]. 医学综述, 2016, 22(13): 2561-2564.
|
[12]
|
Mihrshahi, R. and Brown, M.H. (2010) Downstream of Tyrosine Kinase 1 and 2 Play Opposing roles in CD200 Receptor Signaling. The Journal of Immunology, 185, 7216-7222. https://doi.org/10.4049/jimmunol.1002858
|
[13]
|
Lum, E., Vigliotti, M., Banerjee, N., et al. (2013) Loss of DOK2 Induces Carboplatin Resistance in Ovarian Cancer via Suppression of Apoptosis. Gynecologic Oncology, 130, 369-376. https://doi.org/10.1016/j.ygyno.2013.05.002
|
[14]
|
Niki, M., Di Cristofano, A., Zhao, M., et al. (2004) Role of Dok-1 and Dok-2 in Leukemia Suppression. Journal of Experimental Medicine, 200, 1689-1695. https://doi.org/10.1084/jem.20041306
|
[15]
|
Yasuda, T., Shirakata, M., Iwama, A., et al. (2004) Role of Dok-1 and Dok-2 in Myeloid Homeostasis and Suppression of Leukemia. Journal of Experimental Medicine, 200, 1681-1687. https://doi.org/10.1084/jem.20041247
|
[16]
|
Xu, J., Dong, X., Wang, R., et al. (2022) DOK2 Has Prognostic and Immunologic Significance in Adults with Acute Myeloid Leukemia: A Novel Immune-Related Therapeutic Target. Fron-tiers in Medicine (Lausanne), 9, Article ID: 842383. https://doi.org/10.3389/fmed.2022.842383
|
[17]
|
Chandran, S.S. and Klebanoff, C.A. (2019) T Cell Receptor-Based Cancer Immunotherapy: Emerging Efficacy and Pathways of Resistance. Immunological Reviews, 290, 127-147. https://doi.org/10.1111/imr.12772
|
[18]
|
Park, S., Chapuis, N., Tamburini, J., et al. (2010) Role of the PI3K/AKT and mTOR Signaling Pathways in Acute Myeloid Leukemia. Haema-tologica, 95, 819-828. https://doi.org/10.3324/haematol.2009.013797
|
[19]
|
Nepstad, I., Hatfield, K.J., Gronningsaeter, I.S., et al. (2020) The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. International Journal of Molecular Sciences, 21, 2907.
https://doi.org/10.3390/ijms21082907
|
[20]
|
Cook, A.M., Li, L., Ho, Y., et al. (2014) Role of Altered Growth Factor Receptor-Mediated JAK2 Signaling in Growth and Maintenance of Human Acute Myeloid Leukemia Stem Cells. Blood, 123, 2826-2837.
https://doi.org/10.1182/blood-2013-05-505735
|
[21]
|
Jia, M., Zhang, H., Wang, L., et al. (2021) Identification of Mast Cells as a Candidate Significant Target of Immunotherapy for Acute Myeloid Leukemia. Hematology, 26, 284-294. https://doi.org/10.1080/16078454.2021.1889158
|
[22]
|
Noviello, M., Manfredi, F., Ruggiero, E., et al. (2019) Bone Marrow Central Memory and Memory Stem T-Cell Exhaustion in AML Patients Relapsing after HSCT. Nature Com-munications, 10, Article No. 1065.
https://doi.org/10.1038/s41467-019-08871-1
|
[23]
|
Crowder, R.J., Enomoto, H., Yang, M., et al. (2004) Dok-6, a Novel p62 Dok Family Member, Promotes Ret-Mediated Neurite Outgrowth. Journal of Biological Chemistry, 279, 42072-42081. https://doi.org/10.1074/jbc.M403726200
|
[24]
|
Li, W., Shi, L., You, Y., et al. (2010) Downstream of Tyrosine Kinase/Docking Protein 6, as a Novel Substrate of Tropomyosin-Related Kinase C Receptor, Is Involved in Neurotrophin 3-Mediated Neurite Outgrowth in Mouse Cortex Neurons. BMC Biology, 8, Article No. 86. https://doi.org/10.1186/1741-7007-8-86
|
[25]
|
Leong, S.H., Lwin, K.M., Lee, S.S., et al. (2017) Chromosomal Breaks at FRA18C: Association with Reduced DOK6 Expression, Altered Oncogenic Signaling and Increased Gastric Cancer Survival. NPJ Precision Oncology, 1, Article No. 9. https://doi.org/10.1038/s41698-017-0012-3
|
[26]
|
Kurotsuchi, A., Murakumo, Y., Jijiwa, M., et al. (2010) Analysis of DOK-6 Function in Downstream Signaling of RET in Human Neuroblastoma Cells. Cancer Science, 101, 1147-1155. https://doi.org/10.1111/j.1349-7006.2010.01520.x
|
[27]
|
Sun, G.K., Tang, L.J., Zhou, J.D., et al. (2019) DOK6 Promoter Methylation Serves as a Potential Biomarker Affecting Prognosis in de Novo Acute Myeloid Leukemia. Cancer Medicine, 8, 6393-6402. https://doi.org/10.1002/cam4.2540
|
[28]
|
Gray, S.G., Stenfeldt, M.I. and De Meyts, P. (2003) The Insulin-Like Growth Factors and Insulin-Signalling Systems: An Appealing Target for Breast Cancer Thera-py? Hormone and Metabolic Research, 35, 857-871.
https://doi.org/10.1055/s-2004-814142
|
[29]
|
Blugeon, C., Le Crom, S., Richard, L., et al. (2011) Dok4 Is Involved in Schwann Cell Myelination and Axonal Interaction in Vitro. Glia, 59, 351-362. https://doi.org/10.1002/glia.21106
|
[30]
|
Favre, C., Gerard, A., Clauzier, E., et al. (2003) DOK4 and DOK5: New Dok-Related Genes Expressed in Human T Cells. Genes & Immunity, 4, 40-45. https://doi.org/10.1038/sj.gene.6363891
|
[31]
|
Guan, Y., Li, M., Qiu, Z., et al. (2022) Comprehensive Analysis of DOK Family Genes Expression, Immune Characteristics, and Drug Sensitivity in Human Tumors. Journal of Advanced Research, 36, 73-87.
https://doi.org/10.1016/j.jare.2021.06.008
|
[32]
|
Ohashi, T., Komatsu, S., Ichikawa, D., et al. (2017) Overexpression of PBK/TOPK Relates to Tumour Malignant Potential and Poor Outcome of Gastric Carcinoma. British Journal of Can-cer, 116, 218-226.
https://doi.org/10.1038/bjc.2016.394
|
[33]
|
Ayllon, V. and O’Connor, R. (2007) PBK/TOPK Promotes Tumour Cell Proliferation through p38 MAPK Activity and Regulation of the DNA Damage Response. Oncogene, 26, 3451-3461. https://doi.org/10.1038/sj.onc.1210142
|
[34]
|
Sun, H., Zhang, L., Shi, C., et al. (2015) TOPK Is Highly Expressed in Circulating Tumor Cells, Enabling Metastasis of Prostate Cancer. Oncotarget, 6, 12392-12404. https://doi.org/10.18632/oncotarget.3630
|
[35]
|
Huttlin, E.L., Ting, L., Bruckner, R.J., et al. (2015) The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell, 162, 425-440. https://doi.org/10.1016/j.cell.2015.06.043
|